Teva gets a taste of its own patent-challenge medicine

Teva Pharmaceutical Industries, the generic-drug giant that made a business out of challenging the valuable patents of Big Pharma, is getting a taste of its own tactics as generics makers target its multiple sclerosis drug Copaxone. And it's adopting the same defensive tactics that branded drugmakers have employed against it for years. Report